{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T05:54:35Z","timestamp":1785131675981,"version":"3.55.0"},"reference-count":26,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"11","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO Glob Oncol"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:sec>\n            <jats:title>PURPOSE<\/jats:title>\n            <jats:p>Prior noncontemporary studies showed that oral cyclophosphamide is an active treatment of metastatic castration-resistant prostate cancer (mCRPC). However, cyclophosphamide is currently underutilized in routine clinical practice given the lack of survival benefit and the emergence of more effective treatments.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>METHODS<\/jats:title>\n            <jats:p>We retrospectively reviewed our institutional database to identify patients with mCRPC treated with cyclophosphamide. Prostate-specific antigen decrease \u226550% from baseline (PSA50) response was determined as the proportion of patients achieving a prostate-specific antigen (PSA) decline \u226550% from baseline. Radiographic responses and progression were evaluated by Prostate Cancer Working Group 3. Survival estimates used the Kaplan-Meier method, and correlations were made with Chi-square test for categorical variables.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS<\/jats:title>\n            <jats:p>From January 2011 to January 2023, 341 patients with mCRPC received oral cyclophosphamide at a tertiary cancer center in S\u00e3o Paulo, Brazil. The most common regimen (95%) was 100 mg once daily 21 days on, 7 days off. At prostate cancer diagnosis, the median age was 64.4 years (IQR, 59.4-70.8), 61.9% had metastatic de novo disease, and 55.5% had Gleason \u22658. The median number of previous treatment lines was three (IQR, 2-4). Any PSA decline was observed in 33.4%, and 13.2% had a PSA50 response. Median response duration was 2.1 months (IQR, 1.4-3.8). Ten patients (3%) were treated for \u22651 year. PSA50 response was associated with no prior docetaxel use and Eastern Cooperative Oncology Group performance status 0 or 1.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSION<\/jats:title>\n            <jats:p>Oral cyclophosphamide is a feasible treatment option for patients with mCRPC, particularly in a scenario of limited health care resources.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1200\/go-24-00464","type":"journal-article","created":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T20:59:11Z","timestamp":1738270751000},"update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":1,"title":["Oral Cyclophosphamide for Patients With Metastatic Castration-Resistant Prostate Cancer in a Scenario of Limited Health Care Resources"],"prefix":"10.1200","author":[{"given":"Diana del Cisne","family":"Pineda","sequence":"first","affiliation":[{"name":"Genitourinary Medical Oncology Service, Instituto do C\u00e2ncer do Estado de S\u00e3o Paulo (ICESP), University of S\u00e3o Paulo, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2309-6175","authenticated-orcid":true,"given":"Gabriel Berlingieri","family":"Polho","sequence":"additional","affiliation":[{"name":"Genitourinary Medical Oncology Service, Instituto do C\u00e2ncer do Estado de S\u00e3o Paulo (ICESP), University of S\u00e3o Paulo, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1286-6904","authenticated-orcid":true,"given":"Yumi Ricucci","family":"Shinkado","sequence":"additional","affiliation":[{"name":"Genitourinary Medical Oncology Service, Instituto do C\u00e2ncer do Estado de S\u00e3o Paulo (ICESP), University of S\u00e3o Paulo, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo Alves","family":"Contado","sequence":"additional","affiliation":[{"name":"Genitourinary Medical Oncology Service, Instituto do C\u00e2ncer do Estado de S\u00e3o Paulo (ICESP), University of S\u00e3o Paulo, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalia de Souza","family":"Crusoe","sequence":"additional","affiliation":[{"name":"Genitourinary Medical Oncology Service, Instituto do C\u00e2ncer do Estado de S\u00e3o Paulo (ICESP), University of S\u00e3o Paulo, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian Naomi","family":"Horita","sequence":"additional","affiliation":[{"name":"Genitourinary Medical Oncology Service, Instituto do C\u00e2ncer do Estado de S\u00e3o Paulo (ICESP), University of S\u00e3o Paulo, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joao Carlos","family":"Resende","sequence":"additional","affiliation":[{"name":"Genitourinary Medical Oncology Service, Instituto do C\u00e2ncer do Estado de S\u00e3o Paulo (ICESP), University of S\u00e3o Paulo, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamile Almeida","family":"Silva","sequence":"additional","affiliation":[{"name":"Genitourinary Medical Oncology Service, Instituto do C\u00e2ncer do Estado de S\u00e3o Paulo (ICESP), University of S\u00e3o Paulo, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9133-4086","authenticated-orcid":true,"given":"Guilherme Fialho","family":"de Freitas","sequence":"additional","affiliation":[{"name":"Genitourinary Medical Oncology Service, Instituto do C\u00e2ncer do Estado de S\u00e3o Paulo (ICESP), University of S\u00e3o Paulo, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0661-7960","authenticated-orcid":true,"given":"David Queiroz","family":"Muniz","sequence":"additional","affiliation":[{"name":"Genitourinary Medical Oncology Service, Instituto do C\u00e2ncer do Estado de S\u00e3o Paulo (ICESP), University of S\u00e3o Paulo, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1364-5508","authenticated-orcid":true,"given":"Caio V.","family":"Suartz","sequence":"additional","affiliation":[{"name":"Urology, Instituto do C\u00e2ncer do Estado de S\u00e3o Paulo (ICESP), University of S\u00e3o Paulo, S\u00e3o Paulo, Brazil"},{"name":"Department of Urology, Northern Ontario School of Medicine, Thunder Bay, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9732-6557","authenticated-orcid":true,"given":"Leopoldo Alves","family":"Ribeiro-Filho","sequence":"additional","affiliation":[{"name":"Urology, Instituto do C\u00e2ncer do Estado de S\u00e3o Paulo (ICESP), University of S\u00e3o Paulo, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0065-2194","authenticated-orcid":true,"given":"Paulo M.","family":"Hoff","sequence":"additional","affiliation":[{"name":"Instituto do C\u00e2ncer do Estado de S\u00e3o Paulo (ICESP), University of S\u00e3o Paulo, S\u00e3o Paulo, Brazil"},{"name":"Instituto D\u2019Or de Pesquisa e Ensino, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9510-6956","authenticated-orcid":true,"given":"Jos\u00e9 Mauricio","family":"Mota","sequence":"additional","affiliation":[{"name":"Genitourinary Medical Oncology Service, Instituto do C\u00e2ncer do Estado de S\u00e3o Paulo (ICESP), University of S\u00e3o Paulo, S\u00e3o Paulo, Brazil"},{"name":"Instituto D\u2019Or de Pesquisa e Ensino, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_6_2_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660"},{"key":"e_1_3_6_3_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21708"},{"key":"e_1_3_6_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040720"},{"key":"e_1_3_6_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61389-X"},{"key":"e_1_3_6_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1014618"},{"key":"e_1_3_6_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1405095"},{"key":"e_1_3_6_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1213755"},{"key":"e_1_3_6_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911440"},{"key":"e_1_3_6_10_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01035"},{"key":"e_1_3_6_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy232"},{"key":"e_1_3_6_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1369"},{"key":"e_1_3_6_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.1993.tb16222.x"},{"key":"e_1_3_6_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2010.12.006"},{"key":"e_1_3_6_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-006-0225-8"},{"key":"e_1_3_6_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19930615)71:12<3975::AID-CNCR2820711229>3.0.CO;2-D"},{"key":"e_1_3_6_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11713"},{"key":"e_1_3_6_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11686"},{"key":"e_1_3_6_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2007.01.143"},{"key":"e_1_3_6_20_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-3317"},{"key":"e_1_3_6_21_2","first-page":"4317","article-title":"Metronomic oral cyclophosphamide prednisolone chemotherapy is an effective treatment for metastatic hormone-refractory prostate cancer after docetaxel failure","volume":"30","author":"Ladoire S","year":"2010","unstructured":"Ladoire S, Eymard JC, Zanetta S, et al: Metronomic oral cyclophosphamide prednisolone chemotherapy is an effective treatment for metastatic hormone-refractory prostate cancer after docetaxel failure. Anticancer Res 30:4317-4323, 2010","journal-title":"Anticancer Res"},{"key":"e_1_3_6_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2011.08.010"},{"key":"e_1_3_6_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/ajco.12583"},{"key":"e_1_3_6_24_2","doi-asserted-by":"publisher","DOI":"10.4103\/ijc.IJC_346_17"},{"key":"e_1_3_6_25_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-019-1304-y"},{"key":"e_1_3_6_26_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00120-018-0679-2"},{"key":"e_1_3_6_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2023.11.002"}],"container-title":["JCO Global Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/GO-24-00464","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T20:59:24Z","timestamp":1738270764000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/GO-24-00464"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":26,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["10.1200\/GO-24-00464"],"URL":"https:\/\/doi.org\/10.1200\/go-24-00464","relation":{},"ISSN":["2687-8941"],"issn-type":[{"value":"2687-8941","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"2024-09-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-05","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e2400464"}}